Letters HRT and cardiovascular events

Trial does not change the conclusions of Cochrane review of long term hormone therapy for perimenopausal and postmenopausal women

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e8141 (Published 03 December 2012) Cite this as: BMJ 2012;345:e8141
  1. Jane Marjoribanks, editor, Cochrane Menstrual Disorders and Subfertility Group1,
  2. Cindy Farquhar, postgraduate professor of obstetrics and gynaecology1,
  3. Helen Roberts, associate professor of women’s health, Department of Obstetrics and Gynaecology1,
  4. Anne Lethaby, editor, Cochrane Menstrual Disorders and Subfertility Group1
  1. 1University of Auckland, Auckland 1142, New Zealand
  1. j.marjoribanks{at}auckland.ac.nz

We considered whether to include Schierbeck and colleagues’ trial in our 2012 Cochrane review of long term hormone therapy for perimenopausal and postmenopausal women.1 2

However, it did not meet the inclusion criteria for our review because it had no placebo control group. We also thought that the open label design may have influenced the behaviour of those taking the hormone therapy. Furthermore, we had serious concerns about the use of a composite outcome that was not described in the original study protocol in 1990.

Our review concluded that hormone therapy is not indicated for primary or secondary prevention of cardiovascular disease and that there are insufficient data to assess the risk of long term use in perimenopausal women or postmenopausal women under 50 years of age. These conclusions remain unchanged.

Notes

Cite this as: BMJ 2012;345:e8141

Footnotes

  • Competing interests: None declared.

References